Targeting mTOR in HIV-Negative Classic Kaposi's Sarcoma
Author Information
Author(s): Ofer Merimsky, Irina Jiveliouk, Ronit Sagi-Eisenberg
Primary Institution: Tel-Aviv Sourasky Medical Center
Hypothesis
The mTOR pathway may be important in the tumorigenesis of Kaposi's sarcoma and that rapamycin may have activity in this disease.
Conclusion
This case provides evidence that mTOR targeting with rapamycin can lead to a significant response in a patient with HIV-negative classic Kaposi's sarcoma.
Supporting Evidence
- The patient's soft tissue lesions partially regressed after treatment with rapamycin.
- PET-CT imaging showed a significant decrease in FDG uptake in almost all involved sites.
Takeaway
A 66-year-old woman with a type of skin cancer got better after taking a medicine called rapamycin, which helps fight cancer by targeting a specific pathway in the body.
Methodology
The patient was treated with oral rapamycin, starting with a low dose and gradually increasing it, while monitoring the response with PET-CT imaging.
Limitations
The study is based on a single case report, which limits the generalizability of the findings.
Participant Demographics
A 66-year-old Caucasian female patient.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website